title: In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump.
abstract: BACKGROUND
  This study was designed to assess the stability and potency of insulin aspart under experimental circumstances simulating worst-case conditions during clinical use for continuous subcutaneous insulin infusion (CSII).
  
  
  METHODS
  The potency and stability of two batches of U100 insulin aspart, one recently manufactured and one nearing the end of shelf life, were evaluated after storage in a Medtronic (Northridge, CA) MiniMed 508 pump for up to 7 days at 37 +/- 2 degrees C. The pumps were placed on a vibrating platform (30 +/- 3 oscillations/min, 2 +/- 0.5 cm amplitude displacement) for 24 h/day to simulate movement by the pump user. The product remaining in the pump reservoir was tested at days 3, 4, and 7 and compared with control samples.
  
  
  RESULTS
  After 7 days of in-pump use, there was no significant reduction in potency of insulin aspart or difference from reference values with regards to pH, isoAsp(B28), desamido insulin aspart, insulin aspart-related impurities, or high-molecular-weight proteins. The concentration of phenol and m-cresol remained at levels sufficient to ensure preservative efficacy for both control and test samples. There was no evidence of fibrillation or precipitation.
  
  
  CONCLUSIONS
  The data indicate that storage in the plastic pump reservoir under temperature and vibration conditions simulating worst-case conditions during clinical use for CSII did not affect the stability or potency of insulin aspart significantly, and support an in-pump-use time of 7 days in the MiniMed 508 pump.
authors.affiliation: Novo Nordisk A/S, Bagsvaerd, Denmark. Jbse@novonordisk.com
authors.forename: J
authors.initials: J
authors.lastname: Senstius
authors.forename: E
authors.initials: E
authors.lastname: Harboe
authors.forename: H
authors.initials: H
authors.lastname: Westermann
mesh_terms: D004355:Drug Stability; D006863:Hydrogen-Ion Concentration; D007328:Insulin / Q000031:analogs & derivatives* / Q000737:chemistry; D061267:Insulin Aspart; D007332:Insulin Infusion Systems; D009038:Motion; D011310:Preservatives, Pharmaceutical; D013696:Temperature
chemical_list: D007328:Insulin; D011310:Preservatives, Pharmaceutical; D061267:Insulin Aspart